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Atherosclerotic cardiovascular disease (CVD) remains the major cause of death 
and disability in the US and Europe and is rapidly increasing in the emerging world. 
LDL lowering therapies, while effective in the treatment of CVD, leave a large 
burden of residual risk. The recent CANTOS trial has provided the first direct proof 
that in subjects with evidence of systemic inflammation, targeting inflammatory 
signaling can reduce CVD.1 However, inflammation was broadly defined (elevated 
CRP), and anti-inflammatory therapy was associated with an increased risk of 
infection. Thus, there is an unmet clinical need for a more precise, genetically 
based approach to identify subjects who may benefit from novel therapeutic 
approaches.  
With the support of the Leducq Foundation, seven teams from both sides of the 
Atlantic will join forces to address this challenge. Our Network is led by Alan Tall 
(Columbia University) in the U.S. and Andres Hidalgo (Centro Nacional de 
Investigaciones Cardiovasculares, Madrid, Spain) in Europe. The other project 
leaders are Ben Ebert (Harvard Medical School/Brigham), Sekar Kathiresan 
(Massachussets General Hospital/Broad Institute), Sidd Jaiswal (Stanford 
University), Ira Tabas (Columbia University), Oliver Soehnlein (Ludwig Maximilians 
University) and Steffen Massberg (Ludwig Maximilians University). Other key 
members include Nan Wang (Columbia University) and Christian Schultz (Ludwig 
Maximilians University). We are also most fortunate to have enrolled Peter Libby 
as senior adviser and collaborator. 
Clonal hematopoiesis (CH) represents a clonal expansion of blood cells arising 
from somatic mutations in genes that confer a proliferative advantage to 
hematopoietic stem cells (HSCs).2 Members from our Leducq Network have 
shown that CH, also known as Clonal Hematopoiesis of Indeterminate Potential 
(CHIP), increases in frequency from age 40 onwards, is present in >10% of people 
aged >70 and is associated with a 2-3 fold increased risk of myocardial infarction 
(MI) and stroke, suggesting that CH could be a major non-traditional risk factor 
underlying atherosclerotic CVD.3 CH usually involves mutations in one of four 
genes producing loss of function in epigenetic modifiers (TET2, ASXL1 or 
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DNMT3A) or increased hematopoietic signaling (JAK2). Intriguingly, the 
Kathiresan and Tall laboratories have shown that the most common mutation of 
the JAK2 gene (V617F; JAK2VF) lowers LDL but increases atherosclerosis in both 
mice and humans,4, 5 highlighting a potential dissociation between LDL levels and 
CVD risk in CH. A causal relationship between CH and atherosclerosis was shown 
in mice with Tet2 deficiency and macrophage inflammation, including NLRP3 
inflammasome activation, was identified as a key underlying mechanism.3, 6 Even 
though Tet2-deficient clones expanded in the bloodstream, accelerated 
atherosclerosis occurred without increased numbers of leukocytes in the 
circulation. These findings suggested that targeting inflammation driven by mutant 
leukocytes might be an effective way to reduce CVD risk in CH 
In addition to increased inflammation in myeloid cells, aberrant hematopoiesis may 
increase CVD risk in CH. Although prospectively studied CH subjects did not have 
abnormal total blood cell counts at baseline,3 qualitative changes in blood cell  
function, as well as development of myelo-proliferation in some patients, appears 
likely. Our Leducq team has considerable expertise in studies of aberrant 
hematopoiesis and vascular disease. Tall and colleagues showed that 
hematopoiesis may be driven by hypercholesterolemia, thereby linking myeloid 
cell expansion to atherosclerosis.7, 8 Hidalgo and co-workers have shown that 
platelet-leukocyte aggregates (PLA) are a hallmark of early atherosclerosis9 and 
that polarized neutrophils bound to inflamed endothelium scan the bloodstream for 
activated platelets, thus promoting leukocyte activation and entry into affected 
tissues.10 Soehnlein et al. further demonstrated the importance of neutrophils and 
NETs in early atherogenesis11, and Massberg and colleagues have established 
that platelets and their interactions with myeloid cells play a critical role in lesion 
development and athero-thrombosis.12, 13 Recent collaborative studies by these 
investigators with Wang, Tall, and Tabas at Columbia University using 
hypercholesterolemic Jak2VF mice suggest that macrophage inflammation, 
erythrophagocytosis, failed efferocytosis and inflammation resolution, PLA 
formation and neutrophil NETosis, are all potential mechanisms promoting 
atherosclerosis and thrombosis in CH.5 Moreover, there are likely distinctive 
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mechanisms for each of the four genetic variants underlying CH. In particular 
JAK2VF mice display prominent features of a myeloproliferative state and the 
JAK2VF variant predisposes to NETosis and thrombosis in mice and patients.14 In 
contrast, the other CH mutations give rise to epigenetic changes that promote 
myeloid inflammation and failure of inflammation resolution. The understanding of 
mechanisms linking CH to athero-thrombosis is in its infancy. Therefore this 
network proposes a broad mechanistic approach drawing on the expertise in 
hematopoiesis and atherosclerosis represented by its members (Figure 1).  
 
The overarching goal of our network is to elucidate mechanisms linking CH to 
atherosclerosis as well as other aspects of CVD, and to assess potential 
therapeutic interventions. The overall hypothesis is that CH promotes 
atherosclerosis and thrombosis, and that underlying mechanisms include 
macrophage inflammation, aberrant epigenetic regulation of inflammation, 
inflammasome activation, erythrophagocytosis, abnormal neutrophil and platelet 
functions leading to NET formation and thrombosis, increased PLA formation and 
failed inflammation resolution. The goals of our Network are encompassed by 
three major aims. First, we will explore mechanisms of accelerated atherosclerosis 
in humans with CH. The goal of these analyses will be to obtain insights into how 
CH affects cellular dynamics and gene expression in human atherosclerosis. We 
will use autopsy samples obtained at Stanford (Jaiswal) as well as a Biobank of 
carotid plaque tissue (Soehnlein) to develop methods that allow assessing gene 
expression and CH genotype at the single-cell level from human atherosclerosis 
specimens immediately after death, or from surgical patients. Similarly, blood 
samples from CH carriers with and without CVD, and non-CH controls will be 
analyzed for CH mutations and associated gene expression changes (Kathiresan).  
The Kathiresan team will develop a large, population-based cohort of individuals 
harboring CH, in order to identify factors that promote the association of CH with 
athero-thrombotic disease and to evaluate whether clinical factors (e.g., cigarette 
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smoking and diabetes) or germline genetic variation modulate the association of 
CH with atherosclerotic CVD.  
A second major goal is to investigate mechanisms of atherogenesis and 
thrombosis using mouse models of CH.  Our teams will investigate the hypothesis 
that CH variants increase atherosclerosis and thrombosis, and dissect the 
underlying mechanisms. Mouse models of the four common CH mutations will be 
extensively analyzed in experimental models of athero-thrombosis, myocardial 
infarction and stroke. We will use conditional mouse strains to understand the 
contributions of different cell lineages, including macrophages, neutrophils and 
platelets to these processes. We will also take advantage of CRISPR/Cas9 
technology to evaluate the effects of deletion of specific genes, e.g. up-regulated 
inflammatory genes on atherosclerosis, in the CH mouse models. For example, 
the Ebert and Jaiswal teams will examine whether Dnmt3a and Asxl1 mutations 
have effects on macrophage inflammation and atherogenesis similar to those first 
reported in Tet2-/- mice, and will explore the mechanisms linking these epigenetic 
modifiers to inflammation and atherosclerosis. An unexpected finding from our 
teams is an apparent dysregulation of macrophage-mediated erythrophagocytosis 
and inflammasome activation in mouse models of CH atherosclerosis,5 which will 
be further explored by the Tall team. A role of neutrophils and NETosis in 
atherogenesis and its complications such as plaque erosion and thrombosis is an 
important emerging area and the Soehnlein and Libby/Ebert groups will assess the 
effects of CH on these processes. At the source of intravascular inflammation, 
activated platelets and neutrophils interact to propagate vascular damage;10 
potential dysregulation of these interactions and early vascular damage in the 
context of CH will be studied by the Hidalgo team using advance intravital imaging. 
The consequences of such vasculopathic effects will be also studied in mouse 
models of myocardial infarction and stroke. Because thrombosis is a common 
feature of myelodysplastic syndromes and CH, the Massberg team will evaluate 
alterations in thrombopoiesis and early platelet activation in the bone marrow, as 
well as during athero-thrombosis in mouse models of CH. Finally, the Tabas team 
has recently provided evidence for a key role of defective inflammation resolution 
6 
 
in the atherosclerotic process and will build on preliminary findings showing that 
these processes may be prominently involved in mouse models of CH.  
The final aim of our Network will be to assess potential therapeutic Interventions 
to reduce atherosclerosis in CH using approaches in both humans and mouse 
models. In particular, we aim to explore whether therapies that reduce 
inflammation or LDL will have greater efficacy in CH subjects. To this end, the 
Kathiresan team will assess whether the CH status modifies treatment benefit in 
completed trials of statin and IL-1β therapy where baseline blood samples have 
been collected. Given the recent demonstration that inflammation drives clinical 
atherosclerosis1, the Ebert and Jaiswal teams will examine whether targeting the 
inflammatory products of mutant macrophages, such as IL-1β, can inhibit 
atherosclerosis in mouse models of CH.  An alternative approach will be to explore 
the ability of rHDL infusions and LXR activator treatment to suppress 
inflammasome activation, leukocyte recruitment and atherosclerosis, which will be 
assessed collaboratively by the Tall and Soehnlein team. Finally, mechanisms that 
restore homeostasis and have failed during atherosclerosis will be studied by 
Tabas, whose team will test whether treatment with the resolution mediator 
Resolvlin D1 (RvD1) ameliorates resolution and improves plaque progression in 
the context of CH.   
In addition to our efforts in scientific discovery and therapeutic exploration in CH 
and atherosclerosis, the training and education of emerging investigators is an 
essential goal of our network. Thus, the interweaving of basic and clinical studies 
in network collaborations will provide excellent training for young scientists. 
Moreover, we have established an early stage investigator program, led by Dr 
Soehnlein. This program will feature a mentorship and training plan with a 
dedicated budget and structured review process to support travel and 
collaborations between network laboratories.  It is our ardent hope that at the 
completion of our program we will have gained major new insights into the 
significance of CH in athero-thrombosis, the underlying mechanisms and will have 
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identified potential new treatments that may help to alleviate the major disability 
and death caused by atherosclerosis in our societies.  
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Figure legend  
 
Figure 1. The “Clonal hematopoiesis in atherosclerosis” Leducq Transatlantic Network 
will study multiple aspects of CH-related immune dysregulation, with a focus on 
mutations most commonly associated with CH. We will dissect how these mutations alter 
the function of  hematopoietic progenitors, megakaryocytes/platelets, macrophages, 
10 
 
monocytes and neutrophils in experimental models and in patients, and its 
consequences in inflammation, atherosclerosis and other forms of CVD.  Below are the 
members of the Network, a multidisciplinary team of researchers and clinicians from 
across the US and Europe. 
 
